CA3217608A1 - Idh mutant inhibitor and use thereof - Google Patents

Idh mutant inhibitor and use thereof Download PDF

Info

Publication number
CA3217608A1
CA3217608A1 CA3217608A CA3217608A CA3217608A1 CA 3217608 A1 CA3217608 A1 CA 3217608A1 CA 3217608 A CA3217608 A CA 3217608A CA 3217608 A CA3217608 A CA 3217608A CA 3217608 A1 CA3217608 A1 CA 3217608A1
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
general formula
present
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3217608A
Other languages
English (en)
French (fr)
Inventor
Yuli Xie
Houxing Fan
Lihui QIAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wigen Biomedicine Technology Shanghai Co Ltd
Original Assignee
Wigen Biomedicine Technology Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wigen Biomedicine Technology Shanghai Co Ltd filed Critical Wigen Biomedicine Technology Shanghai Co Ltd
Publication of CA3217608A1 publication Critical patent/CA3217608A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3217608A 2021-06-15 2022-06-15 Idh mutant inhibitor and use thereof Pending CA3217608A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110661394.5 2021-06-15
CN202110661394 2021-06-15
PCT/CN2022/099018 WO2022262784A1 (zh) 2021-06-15 2022-06-15 Idh突变体抑制剂及其用途

Publications (1)

Publication Number Publication Date
CA3217608A1 true CA3217608A1 (en) 2022-12-22

Family

ID=84526875

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3217608A Pending CA3217608A1 (en) 2021-06-15 2022-06-15 Idh mutant inhibitor and use thereof

Country Status (10)

Country Link
US (1) US20240208978A1 (enExample)
EP (1) EP4356914A4 (enExample)
JP (1) JP7884019B2 (enExample)
KR (1) KR20240021774A (enExample)
CN (1) CN117460512A (enExample)
AU (1) AU2022294860A1 (enExample)
BR (1) BR112023024454A2 (enExample)
CA (1) CA3217608A1 (enExample)
MX (1) MX2023013664A (enExample)
WO (1) WO2022262784A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026035776A1 (en) * 2024-08-05 2026-02-12 Frontier Medicines Corporation Pi3k-alpha binding compounds and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012184205A (ja) * 2011-03-08 2012-09-27 Dainippon Sumitomo Pharma Co Ltd ２−アミノ置換８−オキソジヒドロプリン誘導体
SMT202200255T1 (it) * 2012-09-28 2022-07-21 Takeda Pharmaceuticals Co Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea
CA2903979A1 (en) * 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
MA46064B1 (fr) * 2014-09-19 2020-04-30 Forma Therapeutics Inc Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase
US9624175B2 (en) * 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2017019429A1 (en) 2015-07-27 2017-02-02 Eli Lilly And Company 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors
JP6682043B2 (ja) 2016-06-06 2020-04-15 イーライ リリー アンド カンパニー 変異体ｉｄｈ１阻害剤
CN107556366B (zh) * 2016-06-30 2025-02-07 上海海和药物研究开发股份有限公司 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途
KR102232614B1 (ko) * 2016-07-21 2021-03-29 난징 산홈 팔마세우티칼 컴퍼니 리미티드 이소시트레이트 탈수소효소 억제제의 화학적 화합물 및 이의 적용
JP6793836B2 (ja) * 2016-12-16 2020-12-02 イーライ リリー アンド カンパニー 変異体ｉｄｈ１およびｉｄｈ２阻害剤としての７−フェニルエチルアミノ−４ｈ−ピリミド［４，５−ｄ］［１，３］オキサジン−２−オン化合物
CN110872297B (zh) * 2018-09-04 2023-02-14 上海再极医药科技有限公司 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用
WO2020141439A1 (en) * 2018-12-31 2020-07-09 Integral Biosciences Private Limited Heterocyclic compounds as mutant idh inhibitors

Also Published As

Publication number Publication date
EP4356914A1 (en) 2024-04-24
BR112023024454A2 (pt) 2024-02-06
AU2022294860A1 (en) 2024-01-25
MX2023013664A (es) 2024-01-08
KR20240021774A (ko) 2024-02-19
EP4356914A4 (en) 2025-01-08
US20240208978A1 (en) 2024-06-27
JP7884019B2 (ja) 2026-07-02
JP2024524933A (ja) 2024-07-09
WO2022262784A1 (zh) 2022-12-22
CN117460512A (zh) 2024-01-26

Similar Documents

Publication Publication Date Title
CN113717156B (zh) Egfr抑制剂、其制备方法及用途
CA3213029A1 (en) Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof
CN113666923A (zh) 烷氧基烷基取代杂环基类抑制剂及其制备方法和应用
WO2021078285A1 (zh) 环烷基类和杂环烷基类抑制剂及其制备方法和应用
CN115315427B (zh) Hpk1抑制剂及其制备方法和用途
AU2011208139B2 (en) Piperazine compound having a PGDS inhibitory effect
EP3541822A1 (en) Magl inhibitors
US20090118303A1 (en) Serotonin 5-ht3 receptor agonist
JP7761635B6 (ja) Ｇｐｒ５２モジュレーター化合物
IL296413A (en) gpr52 modulator compounds
JP2023528073A (ja) Ｇｐｒ６５モジュレーターとしてのｎ－フェニルアミノカルボニル、ピリジノ－、ピリミジノ及びベンゾトロパン
KR20170096599A (ko) 단백질 키나아제 저해제인 신규 2,3,5-치환된 싸이오펜 화합물
US11760751B2 (en) Benzo 2-azaspiro[4.4]nonane compound and use thereof
CN115974855B (zh) Ezh2和hdac双靶点抑制剂、其药物组合物及其制备方法和用途
EP4356914A1 (en) Idh mutant inhibitor and use thereof
EP4741391A1 (en) Nmt inhibitor, and preparation method therefor and use thereof
RU2860311C2 (ru) Ингибитор мутанта idh и его применение
CN113880804A (zh) 新型苯并咪唑化合物
US12559505B2 (en) IDH mutant inhibitor and use thereof
CN117986269A (zh) 喜树碱衍生物及其制备方法和应用
EP4488267A1 (en) Histamine h3 receptor antagonist and medical use thereof
EP4488263A2 (en) Phenylurea derivative and pharmaceutical use thereof
WO2022257047A1 (en) Diazaspirobicylic compounds as protein-protein interaction inhibitors and applications thereof
HK40121805A (en) Histamine h3 receptor antagonist and medical use thereof
JP2025540298A (ja) Ｈｄａｃ阻害剤およびその使用

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250507

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250507

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260427

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260427

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260501

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260501

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260501

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - SMALL

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260611

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260611